{"transactions":[{"id":2267637,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T17:12:01.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":95800,"price":10.4499,"value":1001100.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.44 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2155930,"source":{"system":"sec-edgar","filing":"0001567619-22-011111","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922011111/doc1.xml","form_type":"4"}},{"id":2267636,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T17:12:01.000Z","date":"2022-05-13","kind":"sale","acquired":false,"shares":35850,"price":10.4453,"value":374464.005,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.43 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2251730,"source":{"system":"sec-edgar","filing":"0001567619-22-011111","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922011111/doc1.xml","form_type":"4"}},{"id":2273244,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-12T20:47:49.000Z","date":"2022-05-12","kind":"sale","acquired":false,"shares":124525,"price":10.394,"value":1294312.85,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.435, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2287580,"source":{"system":"sec-edgar","filing":"0001567619-22-010353","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922010353/doc1.xml","form_type":"4"}},{"id":2273243,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-12T20:47:49.000Z","date":"2022-05-11","kind":"sale","acquired":false,"shares":17700,"price":10.3752,"value":183641.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2412105,"source":{"system":"sec-edgar","filing":"0001567619-22-010353","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922010353/doc1.xml","form_type":"4"}},{"id":2273242,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-12T20:47:49.000Z","date":"2022-05-10","kind":"sale","acquired":false,"shares":18676,"price":10.3807,"value":193869.9532,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2429805,"source":{"system":"sec-edgar","filing":"0001567619-22-010353","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922010353/doc1.xml","form_type":"4"}},{"id":2277360,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-09T18:58:28.000Z","date":"2022-05-09","kind":"sale","acquired":false,"shares":17600,"price":10.374,"value":182582.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2448481,"source":{"system":"sec-edgar","filing":"0001567619-22-009850","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009850/doc1.xml","form_type":"4"}},{"id":2277359,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-09T18:58:28.000Z","date":"2022-05-06","kind":"sale","acquired":false,"shares":48334,"price":10.3702,"value":501233.2468,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2466081,"source":{"system":"sec-edgar","filing":"0001567619-22-009850","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009850/doc1.xml","form_type":"4"}},{"id":2277358,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-09T18:58:28.000Z","date":"2022-05-05","kind":"sale","acquired":false,"shares":20743,"price":10.37,"value":215104.91,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2514415,"source":{"system":"sec-edgar","filing":"0001567619-22-009850","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009850/doc1.xml","form_type":"4"}},{"id":2281938,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-04T19:30:56.000Z","date":"2022-05-04","kind":"sale","acquired":false,"shares":37500,"price":10.3713,"value":388923.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2535158,"source":{"system":"sec-edgar","filing":"0001567619-22-009528","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009528/doc1.xml","form_type":"4"}},{"id":2281937,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-04T19:30:56.000Z","date":"2022-05-03","kind":"sale","acquired":false,"shares":79475,"price":10.3735,"value":824433.9125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2572658,"source":{"system":"sec-edgar","filing":"0001567619-22-009528","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009528/doc1.xml","form_type":"4"}},{"id":2281936,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-04T19:30:56.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":153700,"price":10.3837,"value":1595974.69,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2652133,"source":{"system":"sec-edgar","filing":"0001567619-22-009528","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009528/doc1.xml","form_type":"4"}},{"id":2287745,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T17:50:56.000Z","date":"2022-04-29","kind":"sale","acquired":false,"shares":69230,"price":10.3808,"value":718662.784,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2805833,"source":{"system":"sec-edgar","filing":"0001567619-22-009203","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009203/doc1.xml","form_type":"4"}},{"id":2287744,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T17:50:56.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":73400,"price":10.3806,"value":761936.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2875063,"source":{"system":"sec-edgar","filing":"0001567619-22-009203","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009203/doc1.xml","form_type":"4"}},{"id":2287743,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T17:50:56.000Z","date":"2022-04-27","kind":"sale","acquired":false,"shares":47396,"price":10.3802,"value":491979.9592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2948463,"source":{"system":"sec-edgar","filing":"0001567619-22-009203","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009203/doc1.xml","form_type":"4"}},{"id":2290211,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-26T18:40:39.000Z","date":"2022-04-26","kind":"sale","acquired":false,"shares":64683,"price":10.3823,"value":671558.3109,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2995859,"source":{"system":"sec-edgar","filing":"0001567619-22-008985","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008985/doc1.xml","form_type":"4"}},{"id":2290210,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-26T18:40:39.000Z","date":"2022-04-25","kind":"sale","acquired":false,"shares":27668,"price":10.3876,"value":287404.1168,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3060542,"source":{"system":"sec-edgar","filing":"0001567619-22-008985","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008985/doc1.xml","form_type":"4"}},{"id":2290209,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-26T18:40:39.000Z","date":"2022-04-22","kind":"sale","acquired":false,"shares":37430,"price":10.3883,"value":388834.069,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3088210,"source":{"system":"sec-edgar","filing":"0001567619-22-008985","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008985/doc1.xml","form_type":"4"}},{"id":2292593,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-21T20:54:49.000Z","date":"2022-04-21","kind":"sale","acquired":false,"shares":62200,"price":10.3837,"value":645866.14,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3125640,"source":{"system":"sec-edgar","filing":"0001567619-22-008823","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008823/doc1.xml","form_type":"4"}},{"id":2292592,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-21T20:54:49.000Z","date":"2022-04-20","kind":"sale","acquired":false,"shares":85611,"price":10.3887,"value":889386.9957,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3187840,"source":{"system":"sec-edgar","filing":"0001567619-22-008823","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008823/doc1.xml","form_type":"4"}},{"id":2292591,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-21T20:54:49.000Z","date":"2022-04-19","kind":"sale","acquired":false,"shares":399923,"price":10.4151,"value":4165238.0373,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.44, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3273451,"source":{"system":"sec-edgar","filing":"0001567619-22-008823","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008823/doc1.xml","form_type":"4"}},{"id":2735787,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"5% Convertible Note due 2021","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"price":0,"reported_value":1359799.28,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"expiration_date":"2021-12-31","underlying":"Common Stock","underlying_shares":101457},"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735786,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series C-1 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":13233885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":808259},"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735785,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series C-2 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":8845942,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":540265},"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735784,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series C-3 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":8201930,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":500932},"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735783,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series D Redeemable Convertible Preferred Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":5876034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering (\"IPO\"), and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering (\"IPO\"), and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering (\"IPO\"), and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":358878},"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735782,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"purchase","acquired":true,"shares":450000,"price":15,"value":6750000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2759791,"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735781,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":2309791,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering (\"IPO\"), and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2309791,"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2739580,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"5% Convertible Note due 2021","published_at":"2021-04-26T19:11:06.000Z","date":"2021-04-22","kind":"other","acquired":true,"price":0,"reported_value":1359799.28,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into shares of the issuer's common stock shown in column 7 upon the closing of the issuer's initial public offering (the \"IPO\") at $13.50 per share (90% of the IPO price).  The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into shares of the issuer's common stock shown in column 7 upon the closing of the issuer's initial public offering (the \"IPO\") at $13.50 per share (90% of the IPO price).  The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into shares of the issuer's common stock shown in column 7 upon the closing of the issuer's initial public offering (the \"IPO\") at $13.50 per share (90% of the IPO price).  The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"derivative":{"expiration_date":"2021-12-31","underlying":"Common Stock","underlying_shares":101457},"source":{"system":"sec-edgar","filing":"0000905148-21-000392","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000392/form4.xml","form_type":"4"}},{"id":3059940,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series C Preferred Stock","published_at":"2020-08-12T21:00:18.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":3644624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":487438},"source":{"system":"sec-edgar","filing":"0000905148-20-000880","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000090514820000880/form4.xml","form_type":"4"}},{"id":3059939,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2020-08-12T21:00:18.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":8753350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1314165},"source":{"system":"sec-edgar","filing":"0000905148-20-000880","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000090514820000880/form4.xml","form_type":"4"}},{"id":3059938,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series A Preferred Stock","published_at":"2020-08-12T21:00:18.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":12500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1671771},"source":{"system":"sec-edgar","filing":"0000905148-20-000880","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000090514820000880/form4.xml","form_type":"4"}},{"id":3059937,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-08-12T21:00:18.000Z","date":"2020-08-11","kind":"purchase","acquired":true,"shares":200000,"price":15,"value":3000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3673374,"source":{"system":"sec-edgar","filing":"0000905148-20-000880","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000090514820000880/form4.xml","form_type":"4"}},{"id":3059936,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-08-12T21:00:18.000Z","date":"2020-08-11","kind":"exercise","acquired":true,"shares":3473374,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3473374,"source":{"system":"sec-edgar","filing":"0000905148-20-000880","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000090514820000880/form4.xml","form_type":"4"}},{"id":3078927,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-16","kind":"exercise","acquired":false,"shares":1052950,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1052950},"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078926,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":490411,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":490411},"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078925,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":2398588,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2398588},"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078924,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":3100020,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3100020},"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078923,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":78175,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"The shares are held by Robert Adelman directly."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":78175},"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078922,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":3000,"price":19,"value":57000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"The shares are held by Robert Adelman directly."}],"balance_after":99406,"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078921,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":850000,"price":19,"value":16150000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":5268325,"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078920,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":3941949,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 476,376 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":4418325,"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078919,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":3100020,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 869,618 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3969789,"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078918,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":78175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"Includes 18,231 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"The shares are held by Robert Adelman directly."}],"balance_after":96406,"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3089014,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-07-06T19:00:36.000Z","date":"2020-07-06","kind":"sale","acquired":false,"shares":4603,"price":33.8304,"value":155721.3312,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.07, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3033552,"source":{"system":"sec-edgar","filing":"0000905148-20-000773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000090514820000773/form4.xml","form_type":"4"}},{"id":3089013,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-07-06T19:00:36.000Z","date":"2020-07-02","kind":"sale","acquired":false,"shares":3800,"price":33.633,"value":127805.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $33.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3038155,"source":{"system":"sec-edgar","filing":"0000905148-20-000773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000090514820000773/form4.xml","form_type":"4"}},{"id":3089012,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-07-06T19:00:36.000Z","date":"2020-07-01","kind":"sale","acquired":false,"shares":108064,"price":34.4519,"value":3723010.1216,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $35.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3041955,"source":{"system":"sec-edgar","filing":"0000905148-20-000773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000090514820000773/form4.xml","form_type":"4"}},{"id":3222863,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-06T17:23:19.000Z","date":"2020-03-06","kind":"sale","acquired":false,"shares":1800,"price":23.7949,"value":42830.82,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.41 to $24.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3150019,"source":{"system":"sec-edgar","filing":"0001012975-20-000291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000291/edgar.xml","form_type":"4"}},{"id":3222862,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-06T17:23:19.000Z","date":"2020-03-05","kind":"sale","acquired":false,"shares":8500,"price":23.5307,"value":200010.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3151819,"source":{"system":"sec-edgar","filing":"0001012975-20-000291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000291/edgar.xml","form_type":"4"}},{"id":3222861,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-06T17:23:19.000Z","date":"2020-03-04","kind":"sale","acquired":false,"shares":35650,"price":23.8083,"value":848765.895,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.86 to $24.12, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3160319,"source":{"system":"sec-edgar","filing":"0001012975-20-000291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000291/edgar.xml","form_type":"4"}},{"id":3233122,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T17:52:57.000Z","date":"2020-03-03","kind":"sale","acquired":false,"shares":6401,"price":22.9962,"value":147198.6762,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $23.49, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares reported in Column 5 has been reduced by 10,000 to correct a clerical error in the Reporting Person's Form 4 filed on February 12, 2020 and February 27, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3195969,"source":{"system":"sec-edgar","filing":"0001012975-20-000275","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000275/edgar.xml","form_type":"4"}},{"id":3233121,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T17:52:57.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":10297,"price":23.061,"value":237459.117,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.08, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares reported in Column 5 has been reduced by 10,000 to correct a clerical error in the Reporting Person's Form 4 filed on February 12, 2020 and February 27, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3202370,"source":{"system":"sec-edgar","filing":"0001012975-20-000275","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000275/edgar.xml","form_type":"4"}},{"id":3233120,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T17:52:57.000Z","date":"2020-02-28","kind":"sale","acquired":false,"shares":5100,"price":21.3044,"value":108652.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares reported in Column 5 has been reduced by 10,000 to correct a clerical error in the Reporting Person's Form 4 filed on February 12, 2020 and February 27, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3212667,"source":{"system":"sec-edgar","filing":"0001012975-20-000275","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000275/edgar.xml","form_type":"4"}},{"id":3244064,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-27T19:51:12.000Z","date":"2020-02-27","kind":"sale","acquired":false,"shares":1781,"price":22.54,"value":40143.74,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.40 to $22.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3227767,"source":{"system":"sec-edgar","filing":"0001012975-20-000267","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000267/edgar.xml","form_type":"4"}},{"id":3244063,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-27T19:51:12.000Z","date":"2020-02-26","kind":"sale","acquired":false,"shares":2523,"price":22.4397,"value":56615.3631,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.17 to $22.70, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3229548,"source":{"system":"sec-edgar","filing":"0001012975-20-000267","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000267/edgar.xml","form_type":"4"}},{"id":3244062,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-27T19:51:12.000Z","date":"2020-02-25","kind":"sale","acquired":false,"shares":1600,"price":23.6725,"value":37876.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.64 to $24.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3232071,"source":{"system":"sec-edgar","filing":"0001012975-20-000267","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000267/edgar.xml","form_type":"4"}},{"id":3277249,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T17:56:37.000Z","date":"2020-02-12","kind":"sale","acquired":false,"shares":6,"price":27.14,"value":162.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3233671,"source":{"system":"sec-edgar","filing":"0001012975-20-000119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000119/edgar.xml","form_type":"4"}},{"id":3277248,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T17:56:37.000Z","date":"2020-02-11","kind":"sale","acquired":false,"shares":2184,"price":27.0458,"value":59068.0272,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.28, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3233677,"source":{"system":"sec-edgar","filing":"0001012975-20-000119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000119/edgar.xml","form_type":"4"}},{"id":3277247,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T17:56:37.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":7836,"price":27.0761,"value":212168.3196,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.18, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3225861,"source":{"system":"sec-edgar","filing":"0001012975-20-000119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000119/edgar.xml","form_type":"4"}},{"id":3282210,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-10T17:47:40.000Z","date":"2020-02-06","kind":"sale","acquired":false,"shares":6102,"price":27.0329,"value":164954.7558,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.12, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3233697,"source":{"system":"sec-edgar","filing":"0001012975-20-000115","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000115/edgar.xml","form_type":"4"}},{"id":3286656,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T16:06:35.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":28608,"price":25.9909,"value":743547.6672,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.20 to $26.27, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3239799,"source":{"system":"sec-edgar","filing":"0001012975-20-000113","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000113/edgar.xml","form_type":"4"}},{"id":3286655,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T16:06:35.000Z","date":"2020-02-04","kind":"sale","acquired":false,"shares":53731,"price":25.6496,"value":1378178.6576,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.96, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3268407,"source":{"system":"sec-edgar","filing":"0001012975-20-000113","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000113/edgar.xml","form_type":"4"}},{"id":3311741,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-14T08:58:56.000Z","date":"2020-01-13","kind":"sale","acquired":false,"shares":494000,"price":20.23,"value":9993620.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3322138,"source":{"system":"sec-edgar","filing":"0001012975-20-000033","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000033/edgar.xml","form_type":"4"}},{"id":3313659,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-10T16:06:10.000Z","date":"2020-01-08","kind":"sale","acquired":false,"shares":15677,"price":19.8606,"value":311354.6262,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.67 to $20.30, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3816138,"source":{"system":"sec-edgar","filing":"0001012975-20-000029","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000029/edgar.xml","form_type":"4"}},{"id":3315403,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-08T16:10:35.000Z","date":"2020-01-07","kind":"sale","acquired":false,"shares":31000,"price":20.1661,"value":625149.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.75 to $20.9, inclusive. The Reporting Persons undertake to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within\nthe range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3831815,"source":{"system":"sec-edgar","filing":"0001012975-20-000022","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000022/edgar.xml","form_type":"4"}},{"id":3315402,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-08T16:10:35.000Z","date":"2020-01-06","kind":"sale","acquired":false,"shares":42221,"price":19.6438,"value":829380.8798,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.2025 to $19.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3862815,"source":{"system":"sec-edgar","filing":"0001012975-20-000022","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000022/edgar.xml","form_type":"4"}},{"id":3318712,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-06T16:07:50.000Z","date":"2020-01-03","kind":"sale","acquired":false,"shares":12498,"price":19.3002,"value":241213.8996,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.08 to $19.41, inclusive. The Reporting Persons undertake to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within\nthe range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3905036,"source":{"system":"sec-edgar","filing":"0001012975-20-000013","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000013/edgar.xml","form_type":"4"}},{"id":3318711,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-06T16:07:50.000Z","date":"2020-01-02","kind":"sale","acquired":false,"shares":23000,"price":19.9351,"value":458507.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.69 to $22.33, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3917534,"source":{"system":"sec-edgar","filing":"0001012975-20-000013","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000013/edgar.xml","form_type":"4"}},{"id":3323517,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-03T16:13:39.000Z","date":"2019-12-31","kind":"sale","acquired":false,"shares":14324,"price":23.9639,"value":343258.9036,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $25.55, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3940534,"source":{"system":"sec-edgar","filing":"0001012975-20-000009","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000009/edgar.xml","form_type":"4"}},{"id":3478833,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-06-25T09:20:37.000Z","date":"2019-06-24","kind":"exercise","acquired":false,"shares":722737,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P.  venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P.  Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":235099},"source":{"system":"sec-edgar","filing":"0001012975-19-000449","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297519000449/edgar.xml","form_type":"4"}},{"id":3478832,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-06-25T09:20:37.000Z","date":"2019-06-24","kind":"exercise","acquired":false,"shares":10666667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P.  venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P.  Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3469759},"source":{"system":"sec-edgar","filing":"0001012975-19-000449","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297519000449/edgar.xml","form_type":"4"}},{"id":3478831,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-25T09:20:37.000Z","date":"2019-06-24","kind":"exercise","acquired":true,"shares":235099,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents the total number of shares of common stock received by venBio Global Strategic Fund II, L.P. upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P.  venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P.  Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3954858,"source":{"system":"sec-edgar","filing":"0001012975-19-000449","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297519000449/edgar.xml","form_type":"4"}},{"id":3478830,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-25T09:20:37.000Z","date":"2019-06-24","kind":"exercise","acquired":true,"shares":3469759,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the total number of shares of common stock received by venBio Global Strategic Fund II, L.P. upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P.  venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P.  Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3719759,"source":{"system":"sec-edgar","filing":"0001012975-19-000449","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297519000449/edgar.xml","form_type":"4"}},{"id":3478829,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-25T09:20:37.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":250000,"price":16,"value":4000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 24, 2019, venBio Global Strategic Fund II, L.P. purchased 250,000 shares of common stock of the Issuer at a price of $16.00 per share in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P.  venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P.  Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":250000,"source":{"system":"sec-edgar","filing":"0001012975-19-000449","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297519000449/edgar.xml","form_type":"4"}}]}